торрент для скачивания фильмов на андроид бесплатно
Главное меню:
Интересное
торрент для скачивания фильмов на андроид бесплатно, Merck to acquire Verona Pharma - CNBC, Merck to acquire Verona Pharma for $10 billion | Reuters, Merck to Buy Verona Pharma in $10 Billion Deal — Update, Merck to Acquire Verona Pharma, Expanding its Portfolio to Include , Merck Agrees to Buy Verona Pharma for About $10 Billion, Merck to buy Verona and its lung drug in $10B deal, Merck to buy lung-disease biotech Verona Pharma for $10 billion.
Merck to acquire Verona PharmaNEW!MenuselectSearch quotes, news & videosMenuMerck shells out $10 billion for Verona in bid to diversify beyond KeytrudaPublished Wed, Jul 9 20256:45 AM EDTUpdated Wed, Jul 9 20258:57 AM EDTIn this articleFollow your favorite stocksCREATE FREE ACCOUNTwatch nowVIDEO3:3903:39Merck buys Verona for $10 billion will buy UK-based for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker's respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer treatment.Keytruda, the world's top-selling drug with nearly $30 billion in revenue last year, is nearing key patent expirations from 2028, and Merck has doubled down on efforts to reshape its portfolio.Since 2021, the company has nearly tripled its late-stage pipeline, combining in-house development with acquisitions such as the $11.5 billion purchase of Acceleron in 2021, which netted the pulmonary arterial hypertension drug Winrevair.Wednesday's acquisition is Merck's first of the year and its largest since its $10.8 billion buyout of Prometheus Biosciences in 2023.The deal gives control of Ohtuvayre, a newly approved treatment for chronic obstructive pulmonary disease, a condition commonly called "smoker's lung".The inhaled drug has generated sales of $42.3 million in 2024 and analysts have estimated it could exceed $3 billion in annual revenue.Merck will pay $107 per American depository share for Verona, a premium of 23% to the London-based company's last close on the Nasdaq.Shares in Verona surged 20% in premarket trading, while Merck edged slightly higher."Merck deal looks good at first glance. Given their home run with Prometheus and Winrevair, this (Ohtuvayre) looks like a potential complementary therapy," said Kevin Gade, chief operating officer at Bahl & Gaynor.His sentiment was shared by others, including BMO Capital Markets analyst Evan Seigerman. However, Seigerman added a note of caution, saying more is needed to assure investors of a smooth transition of revenue without a strong decline after Keytruda expiry.News TipsGot a confidential news tip? We want to hear from you.CNBC NewslettersSign up for free newsletters and get more CNBC delivered to your inboxGet this delivered to your inbox, and more info about our products and services.Advertise With Us© 2025 CNBC LLC. All Rights Reserved. , Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker's respiratory treatments., Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry .
Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of , RAHWAY, N.J. & RALEIGH, N.C.– (BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for , Merck & Co. agreed to buy UK biotech Verona Pharma Plc for about $10 billion to offset the looming loss of patent protection on its top-selling cancer drug., Alamy Merck & Co. has agreed to pay $10 billion to buy London-based Verona Pharma, scooping up a potential multibillion-dollar new drug to treat chronic obstructive pulmonary disease in a deal announced Wednesday. The Food and Drug Administration approved Verona’s Ohtuvayre in June 2024 for maintenance treatment of COPD in adults., Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss of revenue once Keytruda patent protection lapses., Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal..